Lu Zheng, Yang Yonglai, Covington Rae-Ann, Bi Yunxia Vivian, Dürig Thomas, Ilies Marc A, Fassihi Reza
School of Pharmacy, Temple University, 3307 N. Broad Street, Philadelphia, PA 19140, USA.
Ashland Specialty Ingredients, 500 Hercules Road, Wilmington, DE 19808, USA.
Int J Pharm. 2016 Sep 25;511(2):957-68. doi: 10.1016/j.ijpharm.2016.07.072. Epub 2016 Aug 2.
Spray dried dispersions (SDDs) of glipizide, a BCS Class II model drug, were prepared using various grades of hydroxypropyl methylcellulose acetate succinate (HPMCAS) and copovidone S-630 as carriers. The SDDs appeared as a single amorphous phase with up to 60% drug loading level as revealed by X-ray powder diffraction (XRPD), modulated differential scanning calorimetry (mDSC) and scanning electron microscopy (SEM). Supersaturated micro-dissolution testing of various SDDs in fasted state simulated intestinal fluid showed prolonged supersaturation state (up to 180min) with solubility increases of 5.2-13.9 fold relative to crystalline drug under similar conditions. Solubility and stability characteristics of the most desirable SDDs in terms of relative dissolution AUCs (AUC(SDD)/AUC(crystalline)) and supersaturated concentration ratios (C180/Cmax) were determined. Results show that HPMCAS-based SDDs achieve a higher degree of supersaturation compared to Copovidone S-630 and that SDDs comprising HPMCAS-M and HPMCAS-H maintained stable supersaturated concentration. Dissolution data showed that SDD-loaded CR tablets provide stable supersaturated concentration within the hydrated matrix with increased rate and extent of drug dissolution over 24h. Co-existence of HPMCAS and HPMC within the hydrating matrix showed strong suppression of drug crystallization and allowed achievement of zero-order and slow-first order release kinetics.
使用不同等级的醋酸羟丙甲纤维素琥珀酸酯(HPMCAS)和共聚维酮S - 630作为载体,制备了BCS II类模型药物格列吡嗪的喷雾干燥分散体(SDD)。X射线粉末衍射(XRPD)、调制差示扫描量热法(mDSC)和扫描电子显微镜(SEM)显示,SDD呈现为单一无定形相,药物载量高达60%。在禁食状态模拟肠液中对各种SDD进行的过饱和微溶出试验表明,相对于类似条件下的结晶药物,过饱和状态延长(长达180分钟),溶解度增加5.2至13.9倍。根据相对溶出曲线下面积(AUC(SDD)/AUC(结晶))和过饱和浓度比(C180/Cmax),确定了最理想的SDD的溶解度和稳定性特征。结果表明,与共聚维酮S - 630相比,基于HPMCAS的SDD实现了更高程度的过饱和,并且包含HPMCAS - M和HPMCAS - H的SDD保持了稳定的过饱和浓度。溶出数据表明,载有SDD的控释片在水合基质中提供稳定的过饱和浓度,药物在24小时内的溶出速率和程度增加。水合基质中HPMCAS和羟丙基甲基纤维素(HPMC)的共存对药物结晶有强烈抑制作用,并实现了零级和缓慢一级释放动力学。